GLG News by Gardasil Prescribers (US)

-Glaxo's Rotarix vaccine was approved last week for prevention of rotavirus infection in infants -Merck's product, Rotateq, on the market for 2 years in the US, already has an established pipeline to essentially all pediatric primary care providers -There are small differences between the 2 vaccines,...

While it is often "nice" to know specifically what virus might be causing symptoms, this knowledge generally has little effect on patient treatment. It might have a public health benefit, in terms of reducing contacts and spread, but this benefit is not generally considered to be cost-efficient (the...

While it is often "nice" to know specifically what virus might be causing symptoms, this knowledge generally has little effect on patient treatment. It might have a public health benefit, in terms of reducing contacts and spread, but this benefit is not generally considered to be cost-efficient (the...

Post marketing studies, required by the FDA, are the lowest form of study. There is no blinding of the investigator, no control group and no ability to quantify risk vs. benefit. There is also no denominator to the numerator of alleged side effects reported, so true risk cannot be assessed.

Sometimes I wonder what I got out of all the years I spent in training?

-Reports of suicidality have been added to Mercks' PI for Singulair -The media have begun to report on this in the past few days and patients are already making calls to their docs -A la Vioxx, Singulair is poised to become the next whipping boy for every depressed asthmatic...

Everyone who thinks that the FDA is going to license a vaccine as costly as Gardasil for boys is insane (sorry if I'm being too subtle). Girls get cervical cancer; the rates of penile and anal cancers from HPV is minuscule in comparison. The cost of Gardasil for girls alone is going to strain a...

The most obvious (potential) benefit to Lilly of its collaboration agreement with Transition is that it will be adding one more potential class of diabetic therapies to its product line.  Lilly already has Humulin (longer-acting insulin), Humalog (a rapid acting insulin), Actos and exenatide (a...

Face the facts: In the US, health care costs are, in large part, demand driven. Sure, there is the supply push issue, but very few physicians actually would subject their patients to unnecessary services or procedures--and those who do continue to face censure and exclusion from insurance plans and...

This is a very interesting concept, especially since RSV, a major cause of illness in very young children, has been difficult to both prevent and treat. Should the process described here pan out, it opens the door to the development of clinical applications.